RESUMO
BACKGROUND: Adherence to treatment after a myocardial infarction (MI) is poor, even in the early postinfarction period. Combining evidence-based drugs into a multicap could improve adherence in this population. No previous randomized trial assessing fixed-dose combination therapy has included patients early after a MI. We aimed to assess if a multicap containing four secondary prevention drugs increases adherence to treatment at 6 months after MI hospitalization. The study was designed as a randomized, parallel, open-label, controlled trial. METHODS: Patients were randomized within 7 days of a MI to either multicap or control group. The multicap group received a capsule containing aspirin, atenolol, ramipril, and simvastatin. The control group received each drug in separate pills. The primary outcome was adherence at 6 months. We also measured blood pressure, heart rate, serum cholesterol levels, C-reactive protein, and platelet aggregation. RESULTS: The study was stopped prematurely when 100 patients were included for futility. At 6 months, 92 (95.8%) patients were adherent to medical treatment: 98.0% in the multicap group and 93.5% in the control group [relative risk (RR) 1.05; 95% confidence interval (CI) 0.96-1.14; p = 0.347]. There were no differences between groups in systolic blood pressure (p = 0.662), diastolic blood pressure (p = 0.784), heart rate (p = 0.533), total cholesterol (p = 0.760), LDL-c (p = 0.979), C-reactive protein (p = 0.399), or in the proportion of patients with adequate platelet aggregation inhibition (p = 0.600). CONCLUSIONS: The study did not find any improvement in the adherence at 6 months after a MI with a multicap-based strategy (Multicap for Increase Adherence After Acute Myocardial Infarction; [ ClinicalTrials.gov identifier: NCT02271178]).
Assuntos
Síndrome Coronariana Aguda/terapia , Antagonistas de Receptores Adrenérgicos beta 1/administração & dosagem , Inibidores da Enzima Conversora de Angiotensina/administração & dosagem , Aspirina/administração & dosagem , Atenolol/administração & dosagem , Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem , Adesão à Medicação , Infarto do Miocárdio/tratamento farmacológico , Inibidores da Agregação Plaquetária/administração & dosagem , Ramipril/administração & dosagem , Sinvastatina/administração & dosagem , Síndrome Coronariana Aguda/sangue , Síndrome Coronariana Aguda/diagnóstico , Síndrome Coronariana Aguda/fisiopatologia , Administração Oral , Antagonistas de Receptores Adrenérgicos beta 1/efeitos adversos , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Argentina , Aspirina/efeitos adversos , Atenolol/efeitos adversos , Combinação de Medicamentos , Feminino , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/sangue , Infarto do Miocárdio/diagnóstico , Infarto do Miocárdio/fisiopatologia , Inibidores da Agregação Plaquetária/efeitos adversos , Ramipril/efeitos adversos , Prevenção Secundária , Sinvastatina/efeitos adversos , Comprimidos , Fatores de Tempo , Resultado do TratamentoRESUMO
Se describen dos casos de lesión de Dieulafoy, la cual es definida como una anormalidad de una arteria grande o arteriola, que conserva su calibre al aproximarse a la mucosa. Esta lesión suele presentarse como sangrado gastrointestinal masivo no doloroso e inestabilidad hemodinámica y puede ser causa de hemorragia gastrointestinal fatal. El diagnóstico definitivo es anatomopatológico aunque con la endoscopia se puede alcanzar una precisión elevada siendo esta última el tratamiento de elección. La enfermedad presentaba una mortalidad cercana al 80% antes de la terapia endoscópica y gracias a esta actualmente se ha reducido al 13%. La experiencia del endoscopista y los recursos disponibles influyen en forma directa con la eficacia en el diagnostico, tratamiento y sobrevida de los pacientes.
Two cases of Dieulafoy lesion, defined as a malformation in a large artery or arteriole that retains its caliber when approaching the mucosa, are described here. This lesion usually causes non-painful massive gastrointestinal bleeding and hemodynamic instability and can cause a fatal gastrointestinal hemorrhage. The definitive diagnosis is pathologic, although a high precision can be achieved by endoscopy, that is the treatment of choice. The disease had a mortality rate near 90% before the endoscopic therapy and, thanks to it, it has currently been reduced to 13%. The endoscopist's experience and the available resources influence directly on the effectiveness of diagnosis, management and survival of patients.
Assuntos
Pediatria , Relatos de Casos , Anormalidades do Sistema Digestório , Endoscopia , Hemorragia GastrointestinalRESUMO
El objetivo es demostrar la eficacia de los equipos de Aféresis de nuestro servicio, en la producción de concentrados plaquetarios y la importancia de que su rendimiento sea óptimo. Para el procedimiento se utilizaron dos tipos de separadores: Separador de Flujo Continuo (Cobe Spectra), y Separador De Flujo Discontinuo: (Haemonetics MCS) que procesa la sangre de forma intermitente a través de un solo acceso venoso. El sistema de ambos es cerrado y el equipo de procedimiento desechable. Los Separadores Celulares han demostrado ser muy eficaces con respecto al recuento del producto final según lo prometido. La demanda de transfusión de plaquetas es elevada, con este tipo de procedimiento se pudo cubrir esa demanda en un 90% de los pedidos de transfusión en nuestro servicio. Los Separadores Celulares han demostrado ser muy eficaces con respecto al recuento del producto final según lo prometido. La demanda de transfusión de plaquetas es elevada, con este tipo de procedimiento se pudo cubrir esa demanda en un 90% de los pedidos de transfusión en nuestro servicio.
